Aulos Bioscience

Aulos Bioscience will present Phase 2 clinical trial data for imneskibart, used in combination with avelumab, in patients with adenocarcinoma non-small cell lung cancer at the ESMO Congress 2026. The announcement signals a key data readout for the company's oncology pipeline, with the findings likely to draw attention from investors and the cancer research community ahead of the congress.